Clinical Trials Browser

Has results × Breast Neoplasms × Magnetic Resonance Spectroscopy × Clear all

NCT03941730 2026-03-05

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Active not recruiting

8 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02226276 2026-02-13

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Phase NA Active not recruiting

10 enrolled 8 charts

Breast Neoplasms

NCT04692103 2026-01-22

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Phase 2 Active not recruiting

2 enrolled 8 charts

Breast Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Completed

190 enrolled 12 charts

Breast Neoplasms

NCT02115282 2025-12-18

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Phase 3 Active not recruiting

608 enrolled 18 charts

Breast Neoplasms

NCT01093612 2025-11-14

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Phase NA Active not recruiting

18 enrolled 6 charts

Breast Neoplasms

NCT02293954 2025-11-14

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

Phase NA Active not recruiting

20 enrolled 8 charts

BreastGastrointestinalThoracic

Bile Duct Neoplasms, Breast Neoplasms, Colonic Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Rectal Neoplasms, Carcinoma, Medullary

NCT02827877 2025-11-14

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Phase 2 Active not recruiting

18 enrolled 8 charts

Breast Neoplasms

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01149083 2025-08-15

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Phase 2 Completed

77 enrolled 17 charts

Breast Neoplasms

NCT01937117 2025-07-01

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Phase 2 Active not recruiting

88 enrolled 15 charts

Breast Neoplasms

NCT04588246 2025-06-06

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

Phase 3 Terminated

19 enrolled 19 charts

BreastCNSDermatologicGastrointestinalGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Small Cell Lung Carcinoma

NCT00618657 2024-02-28

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

Phase 2 Completed

127 enrolled 12 charts

Breast Neoplasms

NCT03831711 2023-12-13

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

Phase 1/2 Completed

5 enrolled 6 charts

Breast Neoplasms

NCT01719562 2023-05-19

MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum

Phase NA Completed

28 enrolled 17 charts

Breast Neoplasms, Neoplasms, Cardiotoxicity

NCT02149173 2021-06-30

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Phase NA Terminated

29 enrolled 9 charts

Breast Neoplasms

NCT00602043 2020-02-19

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Phase 2 Completed

20 enrolled 6 charts

Breast Neoplasms

NCT01720602 2020-01-07

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

Phase NA Completed

15 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01153672 2019-09-06

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

Phase NA Completed

8 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00058058 2019-07-16

ACRIN-6667

Phase NA Completed

1,007 enrolled 9 charts

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT01928186 2018-05-15

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

Phase NA Completed

28 enrolled 16 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00379197 2017-12-28

Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer

Phase 2 Terminated

13 enrolled 4 charts

Breast Neoplasms

NCT00572728 2016-12-30

Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer

Phase 2 Completed

90 enrolled 17 charts

Breast Neoplasms